Loading
Pittsburgh medical oncologist who serves as CEO and Medical Director of the NSABP Foundation, leading its breast cancer trial portfolio.
Priya Rastogi is Chief Executive Officer and Medical Director of the NSABP Foundation and Associate Professor of Medicine at the University of Pittsburgh. A breast medical oncologist, she was first author of the long-term update of the NSABP B-18 and B-27 neoadjuvant chemotherapy trials. She oversees the foundation's clinical trial operations and its participation in the NRG Oncology cooperative group.
| Title | Journal | Year |
|---|---|---|
| Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 | Journal of Clinical Oncology | 2008 |
Shares NSABP Foundation, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer, clinical trials.
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer, clinical trials.
Shares HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.
Shares HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.
Shares HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer, clinical trials.
Shares HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tags leadership, breast cancer.
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.